Investigational Migraine Treatment Reduces Headache Days

Investigative migraine therapy galcanezumab has reported more statistically significant benefits across multiple relevant outcomes in a randomized, placebo-controlled trial that tested 2 different doses of the drug against placebo.

In the most recent results from the Evaluation of LY2951742 in the Prevention of Episodic Migraine 1 (EVOLVE-1) trial, researchers found new clinical benefits for both 120 mg and 240 mg galcanezumab versus placebo in patients with episodic migraines. Patients were randomized 2:1:1 to receive either monthly doses of placebo or either regimen of galcanezumab, respectively.

Led by author Virginia L. Stauffer, PharmD, of Eli Lilly and Company, and corresponding author David W. Dodick, MD, Department of Neurology, Mayo Clinic, Phoenix Arizona, researchers sought the encompassing efficacy and safety of the monoclonal antibody calcitonin gene-related peptide (CGRP) inhibitor in preventing migraines over 6 months.

Click to continue reading on MD Magazine.

For more extensive coverage pertaining to headaches and migraines, check out Specialty Pharmacy Times' sister site, NeurologyLive. The Clinical Focus page hosts hundreds of articles and videos, as well as the most recently released information on data and research.